Interstitial Lung Disease with MCC DRG Reimbursement Guide

DRG 196 designates inpatient stays for interstitial lung disease with a Major Complication or Comorbidity, reflecting higher clinical complexity and resource needs. This matters for inpatient reimbursement because the Major Complication or Comorbidity status increases the Diagnosis-Related Group weight, influencing Medicare payments for the admission.

DRG 196 Overview

DRG 196 covers hospital admissions for interstitial lung disease with a Major Complication or Comorbidity. This category captures complex cases where severe respiratory dysfunction or related organ involvement increases resource use. It is important for Medicare payment because the presence of a Major Complication or Comorbidity raises the relative weight and reimbursable resources for inpatient care. Accurate clinical documentation and coding determine assignment to this higher-severity Diagnosis-Related Group and affect hospital reimbursement.

Acute inpatient management trials focusing on ventilatory and immunomodulatory strategies for hospitalized patients with interstitial lung disease (ILD) experiencing respiratory failure or acute exacerbation. These studies enroll patients admitted with severe hypoxemia, often requiring supplemental oxygen, high-flow nasal cannula, noninvasive ventilation, or mechanical ventilation, and compare different approaches (timing and intensity of respiratory support, corticosteroid regimens, or adjunctive immunosuppressive therapy) to determine short-term clinical outcomes such as in-hospital mortality, need for ICU-level care, and duration of mechanical ventilation. Results inform hospital clinical pathways and resource allocation decisions relevant to payers tracking cost and utilization for this high-acuity DRG.
Comparative effectiveness studies in the inpatient-to-early-postdischarge period evaluating antifibrotic agents, maintenance immunomodulation, or rehabilitation strategies to reduce readmissions and slow disease progression. These studies typically enroll patients hospitalized for ILD complications to compare alternative medication strategies, combination therapies, or initiation timing, and measure outcomes like 30- and 90-day readmission rates, functional status at discharge, and progression on pulmonary function testing. Findings are directly relevant for clinicians deciding in-hospital treatment plans and for payers concerned with downstream costs, readmission penalties, and long-term disease trajectory after a costly hospitalization.
Observational and outcomes research assessing care pathways, comorbidity management, and palliative care integration for complex ILD patients with major complications (MCC) to understand drivers of length of stay, discharge disposition, and end-of-life care. These cohort and registry studies examine heterogeneous inpatients with advanced fibrotic ILD, connective tissue–associated ILD, or drug-related pneumonitis, analyzing how comorbid heart failure, pulmonary hypertension, or infection impact resource use, mortality, and quality-of-life measures. Such evidence helps providers optimize multidisciplinary inpatient care coordination and enables payers to identify high-cost subgroups, target case management, and design bundled payment or value-based programs for this DRG.

Acute inpatient management trials focusing on ventilatory and immunomodulatory strategies for hospitalized patients with interstitial lung disease (ILD) experiencing respiratory failure or acute exacerbation. These studies enroll patients admitted with severe hypoxemia, often requiring supplemental oxygen, high-flow nasal cannula, noninvasive ventilation, or mechanical ventilation, and compare different approaches (timing and intensity of respiratory support, corticosteroid regimens, or adjunctive immunosuppressive therapy) to determine short-term clinical outcomes such as in-hospital mortality, need for ICU-level care, and duration of mechanical ventilation. Results inform hospital clinical pathways and resource allocation decisions relevant to payers tracking cost and utilization for this high-acuity DRG.
Comparative effectiveness studies in the inpatient-to-early-postdischarge period evaluating antifibrotic agents, maintenance immunomodulation, or rehabilitation strategies to reduce readmissions and slow disease progression. These studies typically enroll patients hospitalized for ILD complications to compare alternative medication strategies, combination therapies, or initiation timing, and measure outcomes like 30- and 90-day readmission rates, functional status at discharge, and progression on pulmonary function testing. Findings are directly relevant for clinicians deciding in-hospital treatment plans and for payers concerned with downstream costs, readmission penalties, and long-term disease trajectory after a costly hospitalization.
Observational and outcomes research assessing care pathways, comorbidity management, and palliative care integration for complex ILD patients with major complications (MCC) to understand drivers of length of stay, discharge disposition, and end-of-life care. These cohort and registry studies examine heterogeneous inpatients with advanced fibrotic ILD, connective tissue–associated ILD, or drug-related pneumonitis, analyzing how comorbid heart failure, pulmonary hypertension, or infection impact resource use, mortality, and quality-of-life measures. Such evidence helps providers optimize multidisciplinary inpatient care coordination and enables payers to identify high-cost subgroups, target case management, and design bundled payment or value-based programs for this DRG.

OpenPayer

Summary & Overview

Interstitial Lung Disease with MCC: Inpatient Reimbursement Overview

DRG 196 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes